PT-141 (Bremelanotide)

At a glance

Standard Protocol

Alternative: Micro-Dosing

Alternative Titration 2: 16-week Daily Protocol

Sexual-health protocols are usually acute pathway protocols, so timing and contraindications matter more than chronic escalation. Cardiovascular disease, blood pressure drugs, nitrates, priapism risk, and nausea are key filters. Entry context: target (MC4R; MC3R); route Subcutaneous; timing 4-6 Hours Pre-Activity. Label/trial anchors carry more weight than forum-style escalation.

• Nausea: the primary, most common, and most clinically impactful adverse effect; occurs in the majority of subjects at doses of 1.0mg and above; caused by MC4R activation in the area postrema (chemoreceptor trigger zone); onset within 30-60 minutes of injection; duration typically 1-4 hours; managed by microdosing (500mcg) or prophylactic antiemetics.
• Flushing: facial and upper body flushing from MC3R/MC4R-mediated cutaneous vasodilation; immediate onset; typically lasts 1-2 hours; more pronounced at higher doses.
• Transient blood pressure increase: systolic BP elevation of 6-8 mmHg and diastolic 4-6 mmHg documented in clinical trials; onset within 30 minutes; duration 8-12 hours; the primary cardiovascular safety concern.
• Headache: common; related to the transient blood pressure changes and MC4R-mediated cerebrovascular effects; typically resolves within 1-2 hours.
• Priapism (prolonged erection): rare but serious; unresolved erections lasting more than 4 hours require emergency medical intervention to prevent ischemic penile damage; more likely at higher doses or in predisposed subjects.
• Spontaneous erections: MC4R activation in the hypothalamus produces erections independent of sexual stimulation; a desired effect in the ED indication but problematic in the wrong context.
• Fatigue and lethargy: post-arousal effect as the acute MC4R activation wave resolves; typically 2-4 hours after peak effect.
• Yawning: a distinctive and frequently reported MC4R activation marker; not pathological but a reliable signal of PT-141 activity onset.
• MC4R desensitization with frequent use: the rationale for the 2-dose-per-week maximum; high-frequency MC4R agonism produces receptor downregulation and tachyphylaxis; the 16-week daily protocol's lower doses mitigate this but the 8-week washout is required.
• Transient skin hyperpigmentation: MC1R is activated to a lesser degree than in Melanotan I/II but some subjects note mild transient darkening of moles or skin tone with repeated use.
• Injection site reactions: mild bruising, erythema, and soreness at the subcutaneous site.

• Uncontrolled hypertension: PT-141 produces transient blood pressure increases (both systolic and diastolic) lasting 8-12 hours post-injection via MC4R-mediated sympathetic activation; in subjects with uncontrolled high blood pressure this cardiovascular effect represents meaningful added risk.
• Severe or unstable cardiovascular disease (recent MI, unstable angina, significant arrhythmia): the transient BP elevation and sympathetic activation from MC4R agonism is contraindicated in subjects with marginal cardiovascular reserve.
• History of significant orthostatic hypotension: PT-141 can produce transient hypotension in some subjects as the MC3R vasodilatory component briefly predominates; combined with orthostatic instability this creates fall and syncope risk.
• Concurrent use with PDE5 inhibitors in subjects with cardiovascular disease: while the PT-141/PDE5 inhibitor combination is used in research, in subjects with significant cardiovascular disease the additive vasodilatory and hemodynamic effects require medical supervision.
• Concurrent use with antihypertensive medications: MC4R-mediated sympathetic effects of PT-141 may transiently override antihypertensive therapy and produce unpredictable blood pressure excursions.
• Known hypersensitivity to PT-141, bremelanotide, or melanocortin-derived peptides.
• Pregnancy: MC4R agonism has effects on HPA axis and hypothalamic function not established as safe during pregnancy.
• Breastfeeding: no safety data.
• Active psychiatric conditions requiring mood stabilizers or antipsychotics: MC4R agonism affects dopaminergic tone in limbic circuits that overlap with the targets of these medications.
• History of priapism or predisposition to prolonged erection (sickle cell trait, multiple myeloma, leukemia): PT-141's central arousal mechanism can trigger prolonged erections in predisposed subjects.

Synergistic / related

None listed in the bundled dataset.

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
• https://pubmed.ncbi.nlm.nih.gov/?term=PT-141+%28Bremelanotide%29
• https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=bremelanotide